South Korea-based Bertis has unveiled positive results from its research on protein biomarkers for early diagnosis of high-grade serous ovarian cancer (HGSOC).

The proteomics-based molecular diagnostics company said that the results were published in the Journal of Proteome Research, by the American Chemical Society.

In the study, Bertis’ research team quantified 1,847 serum proteins and identified 18 candidate proteins, using Bertis’ technology platform for biomarker candidates.

The new multi-biomarker panel candidate showed 95% accuracy in identifying HGSOC stages 1 to 3, with 100% sensitivity, and 91% specificity, said the company.

Bertis biomarker research institute head Un-beom Kang said: “This study is significant in that it secured the results of in-depth blood proteome research based on Bertis’ advanced proteomics analysis technology, as well as presented a new biomarker panel with high accuracy for ovarian cancer.

“We expect that based on data from this study, research and development to provide standardised testing for early diagnosis of ovarian cancer will be expedited and the creation of results will be accelerated.”

According to the company, HGSOC is the most common type of ovarian cancer and accounts for nearly 70% of all ovarian cancers.

Most of the patients remain asymptomatic in the early stages, and 70% of the cases could not be detected until the cancer is developed into stage 3 or beyond.

Bertis develops biomarkers for cancer and other major diseases, by combining proteomics and bioinformatics technologies, and provides diagnosis and analysis solutions.

The company offers Mastocheck, a proteomics-based blood test for early diagnosis of breast cancer and PASS, an integrated analysis solution for pan-omics.

Bertis said that it is currently developing early diagnosis solutions for pancreatic cancer, and ovarian cancer, among others.

Bertis CEO Seung-man Han said: “Proteomics analysis is an incredibly effective tool for understanding cancer and discovering new biomarkers for diagnosis and prognosis.

“As a company that has led the discovery of biomarkers based on proteomics technology as well as the development of clinical solutions using it, we will do our best to contribute to the improvement of the diagnosis and treatment of major diseases through continuous research and development.”